Lineal partnered with a Fortune 100 pharmaceutical company to reduce review scope, cost, and risk in a complex IP litigation — applying governed analytics and Amplify Review to eliminate unnecessary first-pass review while preserving defensibility.
Lineal partnered with a Fortune 100 pharmaceutical company to reduce review scope, cost, and risk in a complex IP litigation — applying governed analytics and Amplify Review to eliminate unnecessary first-pass review while preserving defensibility.
